Palisade Bio Past Earnings Performance

Past criteria checks 0/6

Palisade Bio has been growing earnings at an average annual rate of 6%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 99.9% per year.

Key information

6.0%

Earnings growth rate

25.7%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate99.9%
Return on equity-134.0%
Net Marginn/a
Last Earnings Update31 Mar 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Palisade Bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:7NS0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 240-1468
31 Dec 230-1267
30 Sep 230-1368
30 Jun 230-1478
31 Mar 230-1377
31 Dec 220-1597
30 Sep 220-9105
30 Jun 2200114
31 Mar 220-27113
31 Dec 210-2792
30 Sep 210-3292
30 Jun 210-3982
31 Mar 210-1263
31 Dec 200-1063
30 Sep 200-963
31 Dec 190-1073
31 Dec 181-441

Quality Earnings: 7NS0 is currently unprofitable.

Growing Profit Margin: 7NS0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 7NS0 is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.

Accelerating Growth: Unable to compare 7NS0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7NS0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: 7NS0 has a negative Return on Equity (-134.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/03 15:38
End of Day Share Price 2024/04/05 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Palisade Bio, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Aydin HuseynovLadenburg Thalmann & Company
Jason McCarthyMaxim Group